Dr Reddy's shares closed 0.32 per cent higher at Rs 1,284.Drug major Dr Reddy's Laboratories Ltd on Friday reported a 7 per cent year-on-year (YoY) rise in net profit at Rs 1,347 crore for the September quarter, compared with Rs 1,255 crore in the same period last year.
Revenue from operations grew 10 per cent YoY to Rs 8,828 crore, up from Rs 8,038 crore in the corresponding quarter of the previous fiscal.
"Growth in Q2 was driven by momentum in branded markets and steady contributions from the Nicotine Replacement Therapy (NRT) portfolio, which helped offset the decline in US Lenalidomide sales. We remain focused on strengthening our core business, advancing key pipeline assets, driving productivity and pursuing business development initiatives," said GV Prasad, Co-Chairman and MD of Dr Reddy's.
Separately, the company announced that Sanjay Sharma, Global Head of Operations and Senior Management Personnel, has been assigned additional responsibilities of the Chief Human Resources Officer (CHRO) role, effective December 1, 2025.
The appointment follows the resignation of Archana Bhaskar as CHRO, effective November 30, 2025.
The announcements were made post-market hours. Earlier in the day, Dr Reddy's shares closed 0.32 per cent higher at Rs 1,284.
Exam reforms: Tech titan Nandan Nilekani picked by PM Modi to fix national public examination system 
'Tax officers struggled for own land': Nirmala Sitharaman slams laidback attitude of govt depts
CBDT issues new crypto reporting guidance: No new tax, but exchanges must track and report all transactions
Did Cockroach Janta Party's 'Chalo Sansad' 2.0 threat trigger Dharmendra Pradhan's resignation? What we know so far
'Will discharge my responsibilities with complete humility': Pralhad Joshi after being appointed Education Minister
AI Data Centers, Aerospace & Gas Turbines: What's Powering Indo-MIM's Future Growth?
Best Healthcare Stocks: Gaurang Shah's Outlook On Apollo Hospitals, Fortis & The Manipal Health IPO
Is Indo-MIM's IPO Valuation Justified? Here's Why The Company Sees Strong Growth Ahead
Treasury Bills Explained: Why T-Bills Are One Of The Safest Short-Term Investment Options
FDs vs Markets: Where Should You Keep Your Short-Term Money?
Gland Pharma stock: Price target of Rs 3,250 likely in medium term, says analyst 
Metal recycling stocks to buy: Gravita, Pondy Oxides, Jain Resource among top picks
TRIL shares: Should you average the falling stock? Here's 'fixed and final' stop loss
Adani Power: 45 GW target, Rs 2 lakh crore capex plan among conference call highlights 
ITC Hotels, Chalet, Ventive, IHCL, SAMHI: Hotel stocks to buy despite travel disruptions
Beyond mutual funds: Why analysts see SBI Funds' alternative asset business as a long-term growth engine
'Ashamed of it...': Manoj Muntashir calls Adipurush his biggest mistake, seeks country's forgiveness Exam reforms: Tech titan Nandan Nilekani picked by PM Modi to fix national public examination system 'Tax officers struggled for own land': Nirmala Sitharaman slams laidback attitude of govt depts
Delhi targets traffic bottlenecks on Aruna Asaf Ali Marg with ₹1.97 crore elevated road study
